文献速递炎症性肠病

表达IL-23受体的TNFR2+ T细胞扩增与克罗恩病抗TNF治疗分子耐药相关

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
PubMed 文献 · Gut · 2018-05-30

研究对比克罗恩病患者抗TNF治疗前后黏膜与血液细胞,发现应答者治疗前T细胞TNFR2表达显著高于非应答者;治疗期间非应答者黏膜IL-23p19、IL23R、IL-17A显著上调,凋亡抵抗的TNFR2+IL23R+ T细胞扩增,IL-23可消除抗TNF诱导的黏膜T细胞凋亡。

要点

  • 抗TNF治疗前应答者T细胞TNFR2表达显著高于非应答者。
  • 治疗期间非应答者黏膜IL-23p19、IL23R、IL-17A显著上调。
  • 非应答者凋亡抵抗的TNFR2+IL23R+ T细胞显著扩增,IL-23可消除抗TNF诱导的凋亡。

核心结论

  • 凋亡抵抗的肠道TNFR2+IL23R+ T细胞扩增与克罗恩病抗TNF治疗耐药相关,IL-23被确定为抗TNF难治性克罗恩病的合适分子靶点。

研究设计与样本

  • 从克罗恩病患者抗TNF治疗前及治疗期间分离黏膜和血液细胞,采用微阵列、免疫组化、qPCR、ELISA、全器官培养和FACS评估细胞因子谱、细胞表面标志、信号蛋白和细胞凋亡。

主要发现

  • 抗TNF治疗前,应答者T细胞上TNFR2表达显著高于非应答者,而IL23R无此差异。
  • 抗TNF治疗期间,非应答者黏膜IL-23p19、IL23R和IL-17A显著上调,应答者无此变化。
  • 非应答者中凋亡抵抗的TNFR2+IL23R+ T细胞较应答者显著扩增,表达肠道归巢整合素α4β7,且较TNFR2+IL23R-细胞IFN-γ、T-bet、IL-17A和RORγt表达增加,呈混合Th1/Th17样表型。
  • 肠道TNFR2+IL23R+ T细胞可被CD14+巨噬细胞来源的IL-23激活,而CD14+巨噬细胞在抗TNF治疗前非应答者中显著更多。
  • 向抗TNF处理的黏膜器官培养物加入IL-23可导致CD4+IL23R+TNFR2+淋巴细胞扩增,且IL-23可消除抗TNF诱导的黏膜T细胞凋亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anti-tumour necrosis factor (TNF) antibodies are successfully used for treatment of Crohn's disease. Nevertheless, approximately 40% of patients display failure to anti-TNF therapy. Here, we characterised molecular mechanisms that are associated with endoscopic resistance to anti-TNF therapy. DESIGN: Mucosal and blood cells were isolated from patients with Crohn's disease prior and during anti-TNF therapy. Cytokine profiles, cell surface markers, signalling proteins and cell apoptosis were assessed by microarray, immunohistochemistry, qPCR, ELISA, whole organ cultures and FACS. RESULTS: Responders to anti-TNF therapy displayed a significantly higher expression of TNF receptor 2 (TNFR2) but not IL23R on T cells than non-responders prior to anti-TNF therapy. During anti-TNF therapy, there was a significant upregulation of mucosal IL-23p19, IL23R and IL-17A in anti-TNF non-responders but not in responders. Apoptosis-resistant TNFR2+IL23R+ T cells were significantly expanded in anti-TNF non-responders compared with responders, expressed the gut tropic integrins α4β7, and exhibited increased expression of IFN-γ, T-bet, IL-17A and RORγt compared with TNFR2+IL23R- cells, indicating a mixed Th1/Th17-like phenotype. Intestinal TNFR2+IL23R+ T cells were activated by IL-23 derived from CD14+ macrophages, which were significantly more present in non-responders prior to anti-TNF treatment. Administration of IL-23 to anti-TNF-treated mucosal organ cultures led to the expansion of CD4+IL23R+TNFR2+ lymphocytes. Functional studies demonstrated that anti-TNF-induced apoptosis in mucosal T cells is abrogated by IL-23. CONCLUSIONS: Expansion of apoptosis-resistant intestinal TNFR2+IL23R+ T cells is associated with resistance to anti-TNF therapy in Crohn's disease. These findings identify IL-23 as a suitable molecular target in patients with Crohn's disease refractory to anti-TNF therapy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Schmitt H, Billmeier U, Dieterich W, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut. 2018. PMID: 29848778. doi:10.1136/gutjnl-2017-315671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。